Unraveling the therapeutic potential of the LncRNA-dependent noncanonical Hedgehog pathway in cancer.
Acquired resistance to Hedgehog pathway inhibitors has been reported in the clinical setting and upregulation of noncanonical Hedgehog signaling is one of the major underlying mechanisms behind this resistance. As demonstrated in our recent study, greater clinical efficacy might be achieved by focusing on downstream targets of the chemokine-activated noncanonical Hedgehog signaling pathway such as BCAR4 and phospho-GLI2 (Ser149).
Department of Molecular and Cellular Oncology; The University of Texas MD Anderson Cancer Center ; Houston, TX, USA.
Zhen
Z
Xing
Department of Molecular and Cellular Oncology; The University of Texas MD Anderson Cancer Center; Houston, TX, USA; Cancer Biology Program; The University of Texas Graduate School of Biomedical Sciences; Houston, TX, USA.
Chunru
C
Lin
Department of Molecular and Cellular Oncology; The University of Texas MD Anderson Cancer Center; Houston, TX, USA; Cancer Biology Program; The University of Texas Graduate School of Biomedical Sciences; Houston, TX, USA; The Center for RNA Interference and Non-Coding RNAs; The University of Texas MD Anderson Cancer Center; Houston, TX, USA.
Liuqing
L
Yang
BCAR4; Hedgehog Gli2; Long non-coding RNA; breast cancer; cancer treatment; locked nucleic acid; lung metastasis; signaling pathway